Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US

  • The FDA has granted Fast Track designation to Sutro Biopharma Inc's STRO STRO-002 for ovarian cancer.
  • The designation covers platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received one to three prior lines of systemic therapy.
  • STRO-001-GM1 is a Phase 1 trial for STRO-002 for patients with advanced ovarian cancer that have progressed or relapsed after standard of care treatments to assess efficacy, safety, and tolerability. 
  • STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: STRO shares are up 4.09% at $19.60 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsFast Track DesignationOvarian CancerPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!